NASDAQ: RYZB - RayzeBio, Inc. Common Stock

Yield per half year: 0%
Sector: Healthcare

Share chart RayzeBio, Inc. Common Stock

Extended chart Simple chart
Financial Markets by TradingView

About

RayzeBio, Inc. develops radiopharmaceutical therapeutics (RPT) for the treatment of cancer. The company's lead drug candidate is RYZ101, which is in phase 3 clinical trial for the treatment of gasteroenteropancreatic neuroendocrine tumors (GEP-NETs).

More details
It also develops RYZ801, a novel proprietary peptide that targets GPC3 for delivery of Ac225 for the treatment of hepatocellular carcinoma (HCC); RYZ811, a paired diagnostic imaging agent with the peptide binder, chelator, and Ga68 as the radioisotope; and a novel proprietary small molecule that targets CA9 for delivery of Ac225 for the treatment of ccRCC. The company was incorporated in 2020 and is based in San Diego, California.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

Цена ао 62.49
ISIN US75525N1072
EBITDA -0.0067
EV/EBITDA 21.31
Сайт https://rayzebio.com
Валюта usd
IPO date 2023-09-14
Sector Health Care
Industry Biotechnology
Валюта отчета usd
Change price per day: 0% (62.49)
Change price per week: 0% (62.49)
Change price per month: 0% (62.49)
Change price per 3 month: 0% (62.49)
Change price per half year: 0% (62.49)
Change price per year: +202.91% (20.63)
Change price per year to date: +204.24% (20.54)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV 0 0
P/E 0 0
EV/EBITDA 0 0
Total: 2.5

Efficiency

Title Value Grade
ROA, % 0 0
ROE, % 0 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA 0 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % 0 0
Yield Ebitda, % 953.57 10
Yield EPS, % 2126.11 10
Total: 8
More

Institutions Volume Share, %
Viking Global Investors, L.P. 6642700 11.09
venBio Partners LLC 5158162 8.61
Versant Venture Management, LLC 5158161 8.61
VR Adviser, LLC 4030471 6.73
Wellington Management Group, LLP 3504409 5.85
Sofinnova Investments, Inc. 2419528 4.04
Orbimed Advisors LLC. 2365213 3.95
Redmile Group, LLC 1857706 3.1
Samsara BioCapital, LLC 1845948 3.08
Blackrock Inc. 1368838 2.28



Head Job title Payment Year of birth
Dr. Kenneth Song M.D. President, CEO & Director 646k 1975 (49 years)
Mr. Arvind Kush Chief Financial Officer 714.76k 1983 (41 year)
Dr. Susan Moran M.D. Chief Medical Officer 559.84k 1969 (55 years)
Mr. Aron Marc Knickerbocker Co-Founder N/A 1969 (55 years)
Mr. Jeff Woodley General Counsel N/A
Mr. Eric Bischoff Senior Vice President of Development & Operations N/A
Dr. Gary G. Li Ph.D. Senior Vice President of Biology & Translational Medicine N/A
Ms. Kimberly Ma M.S. Senior Vice President of Clinical Operations N/A
Dr. Nicholas D. Smith Ph.D. Senior Vice President of Chemistry Innovation N/A
Mr. Abhi Bhat Ph.D. Senior VP of Chemistry & Head of Discovery N/A

Address: United States, San Diego. CA, 5505 Morehouse Drive - open in Google maps, open in Yandex maps
Website: https://rayzebio.com